Bolufer-Gilabert P, Lluch-Hernández A, Miralles-Dolz F
Departamento de Biopatología Clínica, Centro Maternal, Hospital La Fe, Valencia, España.
Rev Esp Fisiol. 1990 Mar;46(1):103-8.
Epidermal growth factor receptor (EGFr) and cytosolic (cER) and nuclear (nER) estradiol receptors were quantified in 220 primary breast cancers. The EGFr was significantly more frequent (X2 = 5.9; P less than 0.025) and its concentration was significantly higher (P less than 0.001) among ER- tumors than in ER+ tumors. There was a significantly greater proportion (X2 = 6.4; P less than 0.05) of node involvement in EGFr+/ER+ tumors than in EFGr/ER+. Increases in the proportion of EGFr+ in ER- tumors are parallel to Scarff-Bloom scores (X2 = 6.1; P less than 0.05) and there is a significant trend towards increased EGFr concentrations with histologic dedifferentiation. In ER+ tumors the median concentrations of EGFr in the different age groups show linear correlation and follow a parallel profile with the medians of nER. These findings support the hypothesis that considers EGFr as a bad prognosis factor and suggest that EGFr expression and concentration in ER+ tumors might be considered an estrogenic action mediated through the binding of ER to their nuclear acceptors.
在220例原发性乳腺癌中对表皮生长因子受体(EGFr)以及胞质(cER)和核(nER)雌二醇受体进行了定量分析。在雌激素受体阴性(ER-)肿瘤中,EGFr的出现频率显著更高(X2 = 5.9;P小于0.025),且其浓度显著更高(P小于0.001),相比之下,在雌激素受体阳性(ER+)肿瘤中则不然。与EGFr阴性/雌激素受体阳性(EFGr/ER+)肿瘤相比,EGFr阳性/雌激素受体阳性(EGFr+/ER+)肿瘤中淋巴结受累的比例显著更高(X2 = 6.4;P小于0.05)。雌激素受体阴性肿瘤中EGFr阳性比例的增加与斯卡夫-布卢姆(Scarff-Bloom)评分平行(X2 = 6.1;P小于0.05),并且随着组织学去分化,EGFr浓度有显著升高的趋势。在雌激素受体阳性肿瘤中,不同年龄组EGFr的中位浓度呈线性相关,并且与核雌激素受体(nER)的中位数呈现平行趋势。这些发现支持将EGFr视为不良预后因素的假说,并表明雌激素受体阳性肿瘤中EGFr的表达和浓度可能被认为是通过雌激素受体与其核受体结合介导的一种雌激素作用。